Why Asia is the Emerging Epicenter for Global Biopharmaceutical Progress

Asia is quickly becoming a powerhouse for biopharma innovation, changing ideas about where breakthrough science and fast, cost-efficient drug development happen. A new McKinsey & Company report shows how countries like China, Japan, and India are each building their own strengths across the drug development continuum. We spoke to Fangning Zhang, a partner in McKinsey’s Shanghai office, about what’s driving this shift, how it could make innovation more affordable, and why treating Asia as optional may mean missing the next wave of global R&D.

You can listen to Why Asia is the Emerging Epicenter for Global Biopharmaceutical Progress online on Radio and Podcast. Open the player on this page to stream the available audio.

Why Asia is the Emerging Epicenter for Global Biopharmaceutical Progress is an episode from The Bio Report by Levine Media Group.

This episode is 40:20 long.

This episode was published on Mar 4, 2026.

Yes. Use the heart button on the episode page to add it to your favorite episodes list.

Yes. This page shows related episodes from The Bio Report when more episodes are available from the podcast feed.